Brief: MeiraGTx Announces Positive Preliminary Data from the Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings

07/12/2021 13:01

Dec 7 (Reuters) - MeiraGTx Holdings PLC  MGTX.O :
    * MEIRAGTX ANNOUNCES POSITIVE PRELIMINARY DATA FROM THE
AQUAX
PHASE 1 CLINICAL TRIAL OF AAV-HAQP1 FOR THE TREATMENT OF GRADE
2/3 RADIATION-INDUCED XEROSTOMIA
    * MEIRAGTX - CLINICALLY MEANINGFUL IMPROVEMENTS IN
XEROSTOMIA
SYMPTOMS AND DISEASE BURDEN REPORTED IN TWO VALIDATED PATIENT
REPORTED OUTCOME MEASURES
    * MEIRAGTX HOLDINGS PLC - AAV-HAQP1 APPEARS SAFE AND
WELL-TOLERATED AT EACH DOSE TESTED

Source text for Eikon:  ID:nGNX9xdxPY 
Further company coverage:  MGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;;))